Biofrontera Inc.
Business
Biofrontera Inc. is a U.S. biopharmaceutical company developing, manufacturing, and commercializing pharmaceutical products for dermatological conditions, with a focus on photodynamic therapy (PDT). Its principal product is Ameluz, a prescription drug used in combination with RhodoLED Lamps for treating actinic keratosis (AK) and, via pipeline assets, superficial basal cell carcinoma and actinic keratosis on trunk and extremities. The company sells directly to dermatology offices and groups in the United States through its own sales force. Biofrontera maintains a clinical pipeline expanding Ameluz's label indications and improving RhodoLED Lamp capabilities to address larger treatment areas and additional skin conditions.
Summary from 10-K filed 2026-03-19
Financials
Consolidated Statement of Income
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Product revenues, net | 42 | 37 | 34 | 29 | 24 | |
| Revenues, related party | — | 18,000 | 66,000 | 133,000 | — | |
| Total revenues, net | 42 | 37 | 34 | 29 | 24 | |
| Selling, general and administrative | 38 | 34 | 39 | 35 | 37 | |
| Selling, general and administrative, related party | 619,000 | 42,000 | — | — | — | |
| Research and development | 4 | 2 | 77,000 | — | — | |
| Total operating expenses | 53 | 55 | 57 | — | — | |
| Loss from operations | −11 | −17 | −23 | −19 | −25 | |
| Change in fair value of warrant liabilities | 899,000 | 2 | 6 | 19 | −13 | |
| Change in fair value of investment, related party | 2,000 | −14,000 | −7 | 2 | — | |
| Loss on debt extinguishment | — | −316,000 | — | — | — | |
| Interest expense, net | −452,000 | −2 | −468,000 | — | — | |
| Other income, net | 388,000 | 158,000 | −75,000 | 33,000 | 689,000 | |
| Total other income (expense) | 837,000 | −527,000 | 3 | 18 | −12 | |
| Loss before income taxes | −11 | −18 | −20 | −608,000 | −38 | |
| Income tax expense | 25,000 | 22,000 | 14,000 | 32,000 | 56,000 | |
| Net loss | −11 | −18 | −20 | −640,000 | −38 | |
| Basic (per share) | −1.04 | −3.22 | −13.02 | −0.61 | −4.28 | |
| Diluted (per share) | −1.04 | −3.22 | −13.02 | −0.61 | — | |
| Basic (shares) | 10 | 6 | 2 | 1 | 9 | |
| Diluted (shares) | 10 | 6 | 2 | 1 | — |
Consolidated Balance Sheet
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2024 2024-09-30 | FY 2023 2023-12-31 | FY 2022 2022-12-31 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 6 | 6 | — | 1 | 17 | |
| Investment, related party | 9,000 | 7,000 | — | — | 11 | |
| Accounts receivable, net | 7 | 5 | — | 5 | 4 | |
| Inventories | 1 | 7 | — | 11 | 7 | |
| Prepaid expenses and other current assets | 2 | 527,000 | — | 425,000 | 810,000 | |
| Asset held for sale | — | 2 | 2 | — | — | |
| Total current assets | 18 | 21 | — | 23 | 43 | |
| Inventories, long term | 4 | — | — | — | — | |
| Property and equipment, net | 2 | 80,000 | — | 134,000 | 204,000 | |
| Operating lease right-of-use assets | 2 | 903,000 | — | 2 | 2 | |
| Intangible assets, net | 3 | 35,000 | — | 3 | 3 | |
| Other assets | 360,000 | 383,000 | — | 482,000 | 320,000 | |
| Total assets | 29 | 22 | — | 28 | 51 | |
| Operating lease liabilities | 332,000 | 548,000 | — | 691,000 | 498,000 | |
| Accrued expenses and other current liabilities | 5 | 4 | — | 4 | 11 | |
| Total current liabilities | 12 | 12 | — | 18 | 21 | |
| Convertible notes payable | 5 | 4 | — | — | — | |
| Warrant liabilities | 351,000 | 1 | — | 4 | 3 | |
| Operating lease liabilities, non-current | 1 | 276,000 | — | 804,000 | 848,000 | |
| Other liabilities | 9,000 | 23,000 | — | 37,000 | 21,000 | |
| Total liabilities | 18 | 18 | — | 23 | 27 | |
| Commitments and contingencies (see Note 20) | — | — | — | — | — | |
| Preferred Stock | — | — | — | — | — | |
| Common Stock, $0.001 par value, 70,000,000 shares authorized; 11,648,323 and 8,873,932 shares issued and outstanding as of December 31, 2025 and 2024, respectively | 12,000 | 9,000 | — | 2,000 | 1,000 | |
| Additional paid-in capital | 138 | 122 | — | 104 | 103 | |
| Accumulated deficit | −128 | −117 | — | −100 | −80 | |
| Total stockholders equity | 10 | 4 | — | 5 | 24 | |
| Total liabilities and stockholders equity | 29 | 22 | — | 28 | 51 |
Consolidated Statement of Cash Flows
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Depreciation and amortization | 138,000 | 421,000 | — | — | — | |
| Reduction in the carrying amount of right-of-use assets | 730,000 | 728,000 | 560,000 | 653,000 | — | |
| Stock-based compensation | 951,000 | 1 | 1 | 2 | 129,000 | |
| Non-cash interest expense | 491,000 | 297,000 | 402,000 | 358,000 | 358,000 | |
| Allowance for credit losses | −69,000 | 162,000 | 122,000 | 106,000 | 44,000 | |
| Gain on sale of asset held for sale | −700,000 | — | — | — | — | |
| Loss from termination of operating leases | 19,000 | — | — | — | — | |
| Realized/unrealized loss in investment, related party | −2,000 | 14,000 | 7 | −2 | — | |
| Accounts receivable | −2 | −315,000 | −2 | −70,000 | −612,000 | |
| Other receivables, related party | — | 2,000 | 6 | 5 | −11 | |
| Prepaid expenses and other assets | −2 | −141,000 | 174,000 | 4 | — | |
| Other assets, related party | −686,000 | 5 | −5 | — | — | |
| Inventories | 1 | 4 | −4 | −3 | 3 | |
| Accounts payable | −2,000 | −1 | 2 | — | — | |
| Accounts payable, related parties, net | −533,000 | −355,000 | 4 | — | — | |
| Operating lease liabilities | −683,000 | −689,000 | −657,000 | −781,000 | — | |
| Accrued expenses and other liabilities | 610,000 | −230,000 | −6 | −4 | — | |
| Cash flows used in operating activities | −13 | −10 | −25 | −16 | −27 | |
| Proceeds from sale of asset held for sale | 3 | — | — | — | — | |
| Sales of investment, related party | — | 57,000 | 600,000 | — | — | |
| Purchase of intangible assets | — | −50,000 | — | — | — | |
| Purchases of property and equipment | −2,000 | −10,000 | −5,000 | −38,000 | — | |
| Cash flows provided by (used in) investing activities | 3 | −3,000 | 619,000 | −5 | −11,000 | |
| Proceeds from issuance of Series C preferred stock, net of offering costs | 11 | — | — | — | — | |
| Proceeds from issuance of Series B-1 preferred stock and warrants to purchase series B-3 preferred stock, net of issuance costs | — | 8 | — | 9 | — | |
| Proceeds from issuance of Series B-3 preferred stock from exercise of warrants | — | 7 | — | — | — | |
| Proceeds from issuance of convertible notes, net of issuance costs | — | 4 | — | — | — | |
| Payment of principal short-term debt | — | −4 | −21 | — | — | |
| Cash flows provided by financing activities | 11 | 15 | 8 | 14 | 43 | |
| Net increase in cash and cash equivalents | 487,000 | 5 | −16 | −7 | 16 | |
| Interest paid | 6,000 | 2 | 125,000 | 1,000 | 2,000 | |
| Income tax paid, net | 25,000 | 24,000 | 15,000 | 32,000 | 56,000 | |
| Preferred stock issued as consideration in asset purchase acquisition (See Note 3. Asset Acquisition) | 5 | — | — | — | — | |
| Property, plant and equipment acquired | 2 | — | — | — | 8,000 | |
| Intangible asset acquired | 3 | — | — | — | — | |
| Addition of right-of-use assets in exchange for operating lease liabilities | 1 | 55,000 | 800,000 | — | — |
Filings
Material Events
Insiders
Institutional Holders
Frequently asked questions
What is Biofrontera Inc.'s CIK number?
Biofrontera Inc.'s SEC CIK number is 0001858685 (1858685). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find Biofrontera Inc.'s SEC filings?
All of Biofrontera Inc.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.
When did Biofrontera Inc. last report earnings?
Biofrontera Inc. (BFRI) most recently filed an earnings 8-K with the SEC on May 14, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001493152-26-022875). This is Biofrontera Inc.'s most recent earnings filing of record — not a forecast of its next earnings date.
What is Biofrontera Inc.'s most recent earnings 8-K?
Biofrontera Inc.'s latest earnings 8-K (Item 2.02) was filed May 14, 2026 under accession 0001493152-26-022875. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.
View Biofrontera Inc.'s latest earnings 8-K →
Look up any company's CIK number →